AKBA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Akebia Therapeutics Inc (AKBA) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown revenue growth, its declining net income and EPS, coupled with neutral trading sentiment and no significant positive catalysts, suggest that it is better to hold off on investing in this stock for now.
The MACD is slightly positive at 0.0239 and contracting, RSI is neutral at 54.403, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 1.392, with resistance at 1.528 and support at 1.257.
Revenue increased by 23.93% YoY in Q4 2025, and gross margin improved significantly to 82.06%, up 41.56% YoY.
Net income dropped by 46.31% YoY, and EPS declined by 50.00% YoY. Analyst price targets have been lowered recently due to lower-than-expected revenue from Vafseo. No significant hedge fund, insider, or congressional trading activity. No recent news or significant event-driven catalysts.
In Q4 2025, revenue grew to $57.62M (up 23.93% YoY), but net income dropped to -$12.24M (down 46.31% YoY), and EPS fell to -0.05 (down 50.00% YoY). Gross margin improved to 82.06%, showing operational efficiency.
BTIG and Piper Sandler both lowered their price targets to $4 from $5 and $6, respectively, while maintaining Buy/Overweight ratings. This reflects cautious optimism but highlights concerns over revenue challenges.
